Mirae Asset Global Investments Co. Ltd. Sells 5,173 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Posted by on May 23rd, 2023

Mirae Asset Global Investments Co. Ltd. cut its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 163,602 shares of the company’s stock after selling 5,173 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.21% of CRISPR Therapeutics worth $6,650,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CRSP. EverSource Wealth Advisors LLC lifted its holdings in shares of CRISPR Therapeutics by 2,440.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 381 shares of the company’s stock worth $25,000 after acquiring an additional 366 shares during the period. Hollencrest Capital Management bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth about $25,000. Whittier Trust Co. lifted its holdings in shares of CRISPR Therapeutics by 224.0% during the 4th quarter. Whittier Trust Co. now owns 674 shares of the company’s stock worth $27,000 after acquiring an additional 466 shares during the period. HM Payson & Co. lifted its holdings in shares of CRISPR Therapeutics by 104.2% during the 4th quarter. HM Payson & Co. now owns 980 shares of the company’s stock worth $40,000 after acquiring an additional 500 shares during the period. Finally, Pinnacle Holdings LLC bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth about $48,000. 71.51% of the stock is owned by institutional investors.

CRISPR Therapeutics Price Performance

CRSP opened at $65.80 on Tuesday. The company has a market capitalization of $5.19 billion, a price-to-earnings ratio of -9.79 and a beta of 1.71. The business’s 50-day moving average price is $50.95 and its two-hundred day moving average price is $50.43. CRISPR Therapeutics AG has a 1 year low of $38.94 and a 1 year high of $86.95.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its earnings results on Monday, May 8th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.97. CRISPR Therapeutics had a negative return on equity of 26.64% and a negative net margin of 516.43%. The firm had revenue of $100.00 million for the quarter, compared to analysts’ expectations of $24.33 million. The business’s quarterly revenue was up 10538.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.32) EPS. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -6.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CRSP. Robert W. Baird started coverage on shares of CRISPR Therapeutics in a report on Monday, March 6th. They set a “neutral” rating and a $46.00 price objective for the company. Bryan, Garnier & Co started coverage on shares of CRISPR Therapeutics in a report on Friday, March 17th. They set a “buy” rating and a $70.00 price target for the company. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $75.00 price target on shares of CRISPR Therapeutics in a report on Monday, April 17th. Credit Suisse Group lowered their price objective on shares of CRISPR Therapeutics from $78.00 to $65.00 and set a “neutral” rating for the company in a research report on Wednesday, February 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, April 20th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $72.58.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 29th. The shares were sold at an average price of $44.46, for a total value of $1,111,500.00. Following the completion of the transaction, the chief executive officer now owns 387,377 shares of the company’s stock, valued at $17,222,781.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 75,000 shares of company stock valued at $3,584,500 over the last 90 days. 5.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.